State Institute of Drugs and Good Practices signed a cooperation agreement with PharmaPharm
On November 14, 2018, the State Institute of Drugs and Good Practices signed a cooperation agreement with the integrated pharmaceutical portal PharmaPharm within the framework of Life Sciences Invest in St. Petersburg. Formal mutual agreement was the first step on the way towards uniting the pharmaceutical community.
The signing took place within the framework of the discussion session dedicated to Transition to a common EAEU market drug circulation that was chaired by Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices.
The mission of the portal is to create an integrated expert platform for effective interaction of all stakeholders of the pharmaceutical community, which in turn will benefit industry as a whole. Cooperation with the State Institute of Drugs and Good Practices will allow for sharing genuine materials of the institute’s leading experts, information exchange, implementation of joint activities and programs, maximum mutually beneficial support for successful association and development of the pharmaceutical community.
«A great number of regulatory issues require professional discussion of experts. Over the past 6-7 years of active growth in the industry, discussions have taken place in the format of many different conferences; most of them – however – leave many questions unanswered. There is a need for an online platform that could guarantee a sufficient number of expert discussions without distracting specialists from work,» — said Zakhar Golant, Board Chairman of the Russian Union of Pharmaceutical and Biomedical Cluster.
The mission of the integrated pharmaceutical portal is to strengthen the expert community by bringing together professionals from all sectors of the industry at one site. Involvement of leading professionals make it possible for the portal to focus on in-depth expertise of industry specific issues. PharmaPharm plans to present a unique analytics from Russian and foreign experts. All significant events will be addressed on the forum and reflected in the expert materials. Opportunities to seek answers from particular categories of experts will increase information outreach on urgent issues and make the community more transparent and open, and – consequently – more effective.
I consider partnership agreements to be an important step on the road towards unification of the pharmaceutical community, and I am very pleased that the State Institute of Drugs and Good Practices is our first partner. We have worked together from the very concept of the pharmaceutical portal, literally from scratch. Also, at Life Sciences Invest, we plan to sign agreements with the Biomedical Cell Products Association, as well as with the Russian Union of Pharmaceutical and Biomedical Cluster’, said Anna Plesovskikh, PharmaPharm Managing Partner.
«It is very important to be constantly available for pharmaceutical manufacturers, timely provide relevant clarifications on all GMP-related issues and other expertise of the institute. Consequently, a position of transparency and accessibility is the most correct way for competent and productive interaction of all industry stakeholders», commented Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices.
- The issues of the legal and regulatory framework of pharmaceutical activities in Russian and the EAEU were discussed by participants of the VI All-Russia Congress
- The experts of FSI «SID & GP» took part in the meeting of Indian manufacturers and suppliers of the pharmaceutical industry with Russian colleagues
- «Requirements and Application of GMP Rules to Manufacture of APIs» – an open expert-advisory workshop
- Russian drugs penetration to the key segments of the pharmaceutical market rose in the 1st half of 2018
- The State Institute of Drugs and Good Practices Of the Ministry of Industry and trade of the Russian federation Celebrates 45th Anniversary